Tetrachlorocatechol

CAS No. 1198-55-6

Tetrachlorocatechol ( —— )

Catalog No. M28190 CAS No. 1198-55-6

Tetrachlorocatechol is a metabolite of pentachlorophenol. Tetrachlorocatechol is one of the most toxic chlorinated catechol produced by the chlorobleaching of pulp and frequently found in the kraft pulp mill effluents.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
200MG 26 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tetrachlorocatechol
  • Note
    Research use only, not for human use.
  • Brief Description
    Tetrachlorocatechol is a metabolite of pentachlorophenol. Tetrachlorocatechol is one of the most toxic chlorinated catechol produced by the chlorobleaching of pulp and frequently found in the kraft pulp mill effluents.
  • Description
    Tetrachlorocatechol is a metabolite of pentachlorophenol. Tetrachlorocatechol is one of the most toxic chlorinated catechol produced by the chlorobleaching of pulp and frequently found in the kraft pulp mill effluents.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Wnt/β-catenin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1198-55-6
  • Formula Weight
    247.9
  • Molecular Formula
    C6H2Cl4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Oc1c(O)c(Cl)c(Cl)c(Cl)c1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang J, et al. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. Bioorg Med Chem. 2018 Nov 1;26(20):5435-5442.
molnova catalog
related products
  • H2DCFDA

    H2DCFDA is a cell-permeable probe. Which is used to detect intracellular reactive oxygen species (ROS).

  • Miglustat

    Miglustat is an alkylated product of imino sugar deoxynojirimycin.It?is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

  • Epiaschantin

    (+)-Epiaschantin shows marginal cancer cell line inhibitory activities. It also has anti-platelet aggregation activity.